XML 39 R27.htm IDEA: XBRL DOCUMENT

Subsequent events	6 Months Ended
Subsequent events	Jun. 30, 2025
Subsequent Events [Abstract]
Subsequent events	Subsequent events The Company has evaluated events subsequent to June 30, 2025 through the date of this filing to assess the need for potential recognition or disclosure. Pluristyx convertible debt On July 18, 2025, the Company purchased $2.0 million of convertible notes in Pluristyx, Inc. ("Pluristyx"), a Seattle-based developer of induced pluripotent stem cell ("iPSC") based products for cell therapy developers. The convertible notes accrue interest at an annual rate of 10% and are payable on October 1, 2028. The Company also entered into a separate agreement which provides a board observer seat, and certain rights related to any potential future acquisition of Pluristyx.